American Journal of Clinical Dermatology

, Volume 11, Issue 6, pp 399–411 | Cite as

Chronic Pruritus in the Absence of Specific Skin Disease

An Update on Pathophysiology, Diagnosis, and Therapy
  • Nicoletta Cassano
  • Gianpaolo TessariEmail author
  • Gino A. Vena
  • Giampiero Girolomoni
Review Article


Chronic pruritus is a major and distressing symptom of many cutaneous and systemic diseases and can significantly impair the patient’s quality of life. Pruritus perception is the final result of a complex network involving dedicated nerve pathways and brain areas, and an increasing number of peripheral and central mediators are thought to be involved. Itch is associated with most cutaneous disorders and, in these circumstances, its management overlaps with that of the skin disease. Itch can also occur without associated skin diseases or primary skin lesions, but only with nonspecific lesions secondary to rubbing or scratching. Chronic itch with no or minimal skin changes can be secondary to important diseases, such as neurologic disorders, chronic renal failure, cholestasis, systemic infections, malignancies, and endocrine disorders, and may also result from exposure to some drugs. The search for the cause of pruritus usually requires a meticulous step-by-step assessment involving careful history taking as well as clinical examination and laboratory investigations.

Few evidence-based treatments for pruritus are available. Topical therapy, oral histamine H1 receptor antagonists, and phototherapy with UV radiation can target pruritus elicitation in the skin, whereas antiepileptic drugs, opioid receptor antagonists, and antidepressants can block signal processing in the CNS.


Atopic Dermatitis Primary Biliary Cirrhosis Naltrexone Polycythemia Vera Nalbuphine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to prepare this review. Each of the authors contributed to the conception of the article and to the literature search and the synthesis and interpretation of the data. Each of the authors drafted and revised the manuscript and approved the final version. The authors have no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Ständer S, Weisshaar E, Mettang T, et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol 2007; 87: 291–4PubMedCrossRefGoogle Scholar
  2. 2.
    Schmelz M, Schmidt R, Bickel A, et al. Specific C-receptors for itch in human skin. J Neurosci 1997; 17: 8003–8PubMedGoogle Scholar
  3. 3.
    Paus R, Schmelz M, Bíró T, et al. Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest 2006; 116: 1174–85PubMedCrossRefGoogle Scholar
  4. 4.
    Tominaga M, Ogawa H, Takamori K. Possible roles of epidermal opioid systems in pruritus of atopic dermatitis. J Invest Dermatol 2007; 127: 2228–35PubMedCrossRefGoogle Scholar
  5. 5.
    Denda M, Nakatani M, Ikeyama K, et al. Epidermal keratinocytes as the forefront of the sensory system. Exp Dermatol 2007; 16: 157–61PubMedCrossRefGoogle Scholar
  6. 6.
    Boulais N, Misery L. The epidermis: a sensory tissue. Eur J Dermatol 2008; 18: 119–27PubMedGoogle Scholar
  7. 7.
    Andrew D, Craig AD. Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci 2001; 4: 72–7PubMedCrossRefGoogle Scholar
  8. 8.
    Steinhoff M, Stander S, Seeliger S, et al. Modern aspects of cutaneous neurogenic inflammation. Arch Dermatol 2003; 139: 1479–88PubMedCrossRefGoogle Scholar
  9. 9.
    Steinhoff M, Vergnolle N, Young SH, et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism.Nat Med 2000; 6: 151–8PubMedCrossRefGoogle Scholar
  10. 10.
    Sun YG, Chen ZF. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 2007; 448: 700–3PubMedCrossRefGoogle Scholar
  11. 11.
    Yosipovitch G, Ishiuji Y, Patel TS, et al. The brain processing of scratching. J Invest Dermatol 2008; 128: 1806–11PubMedCrossRefGoogle Scholar
  12. 12.
    Valet M, Pfab F, Sprenger T, et al. Cerebral processing of histamine-induced itch using short-term alternating temperature modulation: an FMRI study. J Invest Dermatol 2008; 128: 426–33PubMedGoogle Scholar
  13. 13.
    Schmelz M. Itch and pain. Neurosci Biobehav Rev 2010; 34: 171–6PubMedCrossRefGoogle Scholar
  14. 14.
    Stönder S, Schmelz M. Chronic itch and pain: similarities and differences. Eur J Pain 2006; 10: 473–8CrossRefGoogle Scholar
  15. 15.
    Drzezga A, Darsow U, Treede R, et al. Central activation by histamine-induced itch: analogies to pain processing: a correlational analysis of O-15 H(2)O positron emission tomography studies. Pain 2001; 92: 295–305PubMedCrossRefGoogle Scholar
  16. 16.
    Twycross R, Greaves MW, Handwerker H, et al. Itch: scratching more than the surface. QJM 2003; 96: 7–26PubMedCrossRefGoogle Scholar
  17. 17.
    Misery L, Wallengren DJ, Weisshaar E, et al., French Psychodermatology Group. Validation of diagnosis criteria of functional itch disorder or psychogenic pruritus. Acta Derm Venereol 2008; 88: 503–4PubMedCrossRefGoogle Scholar
  18. 18.
    Lee MR, Shumack S. Prurigo nodularis: a review. Australas J Dermatol 2005; 46: 211–8PubMedCrossRefGoogle Scholar
  19. 19.
    Schneider G, Hockmann J, Stönder S, et al. Psychological factors in prurigo nodularis in comparison with psoriasis vulgaris: results of a case-control study. Br J Dermatol 2006; 154: 61–6PubMedCrossRefGoogle Scholar
  20. 20.
    Bork K. Pruritus precipitated by hydroxyethyl starch: a review. Br J Dermatol 2005; 152: 3–12PubMedCrossRefGoogle Scholar
  21. 21.
    Moses S. Pruritus. Am Fam Physician 2003; 68: 1135–42PubMedGoogle Scholar
  22. 22.
    Kantor GR, Lookingbill DP. Generalized pruritus and systemic disease. J Am Acad Dermatol 1983; 9: 375–82PubMedCrossRefGoogle Scholar
  23. 23.
    Perkins GL, Slater ED, Sanders GK, et al. Serum tumor markers. Am Fam Physician 2003; 68: 1075–82PubMedGoogle Scholar
  24. 24.
    Asero R. Food additive-induced chronic pruritus: further evidence. Clin Exp Dermatol 2005; 30: 719–20PubMedCrossRefGoogle Scholar
  25. 25.
    Cohen AD, Vander T, Medvendovsky E, et al. Neuropathic scrotal pruritus: anogenital pruritus is a symptom of lumbosacral radiculopathy. J Am Acad Dermatol 2005; 52: 61–6PubMedCrossRefGoogle Scholar
  26. 26.
    Cohen AD, Masalha R, Medvedovsky E, et al. Brachioradial pruritus: a symptom of neuropathy. J Am Acad Dermatol 2003; 48: 825–8PubMedCrossRefGoogle Scholar
  27. 27.
    Massey EW. Sensory mononeuropathies. Semin Neurol 1998; 18: 177–83PubMedCrossRefGoogle Scholar
  28. 28.
    Bernhard JD, Bordeaux JS. Medical pearl: the ice-pack sign in brachioradial pruritus [letter]. J Am Acad Dermatol 2005; 52: 1073PubMedCrossRefGoogle Scholar
  29. 29.
    Wallengren J. Brachioradial pruritus: a recurrent solar dermopathy. J Am Acad Dermatol 1998; 39: 803–6PubMedCrossRefGoogle Scholar
  30. 30.
    Wallengren J, Klinker M. Successful treatment of notalgia paresthetica with topical capsaicin: vehicle-controlled, double-blind, crossover study. J Am Acad Dermatol 1995; 32: 287–9PubMedCrossRefGoogle Scholar
  31. 31.
    Grossman MG, Ducey SA, Nadler SS. Meralgia paresthetica: diagnosis and treatment. J Am Acad Orthop Surg 2001; 9: 336–44PubMedGoogle Scholar
  32. 32.
    Narita I, Iguchi S, Omori K, et al. Uremic pruritus in chronic hemodialysis patients. J Nephrol 2008; 21: 161–5PubMedGoogle Scholar
  33. 33.
    Patel TS, Freedman BI, Yosipovitch G. An update on pruritus associated with CKD. Am J Kidney Dis 2007; 50: 11–20PubMedCrossRefGoogle Scholar
  34. 34.
    Pisoni RL, Wikström B, Elder SJ, et al. Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2006; 21: 3495–505PubMedCrossRefGoogle Scholar
  35. 35.
    Tessari G, Dalle Vedove C, Loschiavo C, et al. The impact of pruritus on the quality of life of patients undergoing dialysis: a single centre, cohort study. J Nephrol 2009; 22: 241–8PubMedGoogle Scholar
  36. 36.
    Manenti L, Tansinda P, Vaglio A. Uraemic pruritus: clinical characteristics, pathophysiology and treatment. Drugs 2009; 69: 251–63PubMedCrossRefGoogle Scholar
  37. 37.
    Gunal AI, Ozalp G, Yoldas TK, et al. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 2004; 19: 3137–9PubMedCrossRefGoogle Scholar
  38. 38.
    Wikström B, Gellert R, Ladefoged SD, et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 2005; 16: 3742–7PubMedCrossRefGoogle Scholar
  39. 39.
    Wu JJ, Huang DB, Pang KR, et al. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol 2005; 153: 254–73PubMedCrossRefGoogle Scholar
  40. 40.
    Rivard J, Lim HW. Ultraviolet phototherapy of pruritus. Dermatol Ther 2005; 18: 344–54PubMedCrossRefGoogle Scholar
  41. 41.
    Seckin D, Demircay Z, Akin O. Generalized pruritus treated with narrowband UVB. Int J Dermatol 2007; 46: 367–70PubMedCrossRefGoogle Scholar
  42. 42.
    Rutherford AE, Pratt DS. Cholestasis and cholestatic syndromes. Curr Opin Gastroenterol 2006; 22: 209–14PubMedCrossRefGoogle Scholar
  43. 43.
    Chitturi S, Farrell GC. Drug-induced cholestasis. SeminGastrointest Dis 2001; 12: 113–24PubMedGoogle Scholar
  44. 44.
    Bergasa NV. Update on the treatment of the pruritus of cholestasis. Clin Liver Dis 2008; 12: 219–34PubMedCrossRefGoogle Scholar
  45. 45.
    Tandon P, Rowe BH, Vandermeer B, et al. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasisassociated pruritus. Am J Gastroenterol 2007; 102: 1528–36PubMedCrossRefGoogle Scholar
  46. 46.
    Mayo MJ, Handem I, Saldana S, et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007; 45: 666–74PubMedCrossRefGoogle Scholar
  47. 47.
    Gong Y, Huang Z, Christensen E, et al. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using bayesian approach as sensitivity analyses. Am J Gastroenterol 2007; 102: 1799–807PubMedCrossRefGoogle Scholar
  48. 48.
    Singh F, Rudikoff D. HIV-associated pruritus: etiology and management. Am J Clin Dermatol 2003; 4: 177–88PubMedCrossRefGoogle Scholar
  49. 49.
    Rigopoulos D, Paparizos V, Katsambas A. Cutaneous markers of HIV infection. Clin Dermatol 2004; 22: 487–98PubMedCrossRefGoogle Scholar
  50. 50.
    Zancanaro PC, McGirt LY, Mamelak AJ, et al. Cutaneous manifestations of HIV in the era of highly active antiretroviral therapy: an institutional urban clinic experience. J Am Acad Dermatol 2006; 54: 581–8PubMedCrossRefGoogle Scholar
  51. 51.
    Maurer T, Poncelet A, Berger T. Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. Arch Dermatol 2004; 140: 845–9PubMedCrossRefGoogle Scholar
  52. 52.
    Maticic M, Poljak M, Lunder T, et al. Lichen planus and other cutaneous manifestations in chronic hepatitis C: pre- and post-interferon-based treatment prevalence vary in a cohort of patients from low hepatitis C virus endemic area. J Eur Acad Dermatol Venereol 2008; 22: 779–88PubMedCrossRefGoogle Scholar
  53. 53.
    Kleyn CE, Lai-Cheong JE, Bell HK. Cutaneous manifestations of internal malignancy: diagnosis and management. Am J Clin Dermatol 2006; 7: 71–84PubMedCrossRefGoogle Scholar
  54. 54.
    Lidstone V, Thorns A. Pruritus in cancer patients. Cancer Treat Rev 2001; 27: 305–12PubMedCrossRefGoogle Scholar
  55. 55.
    Goldman BD, Koh HK. Pruritus and malignancy. In: Bernhard JD, editor. Itch: mechanisms and management of pruritus. New York: McGraw-Hill, 1994: 299–319Google Scholar
  56. 56.
    McMichael J. Localized itching as a harbinger of breast cancer? J Fam Pract 2004; 53: 562PubMedGoogle Scholar
  57. 57.
    Summers CG, MacDonald JT. Paroxysmal facial itch: a presenting sign of childhood brainstem glioma. J Child Neurol 1988; 3: 189–92PubMedCrossRefGoogle Scholar
  58. 58.
    Magilner D. Localized cervical pruritus as the presenting symptom of a spinal cord tumor. Pediatr Emerg Care 2006; 22: 746–7PubMedCrossRefGoogle Scholar
  59. 59.
    Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007; 110: 840–6PubMedCrossRefGoogle Scholar
  60. 60.
    Cassano N, Lattanzi V, Profeta G, et al. Orticaria e prurito acquagenici. Ann It Derm Allergol Clin Sper 2007; 61: 41–9Google Scholar
  61. 61.
    Daponte A, Ioannou M, Gioti C, et al. Primary retroperitoneal non-Hodgkin lymphoma presenting with torturous generalized pruritus in an elderly. Arch Gynecol Obstet 2007; 275: 287–9PubMedCrossRefGoogle Scholar
  62. 62.
    Robak E, Robak T. Skin lesions in chronic lymphocytic leukemia. Leuk Lymphoma 2007; 48: 855–65PubMedCrossRefGoogle Scholar
  63. 63.
    Jabbour SA. Cutaneous manifestations of endocrine disorders: a guide for dermatologists. Am J Clin Dermatol 2003; 4: 315–31PubMedCrossRefGoogle Scholar
  64. 64.
    Bharati A, Yesudian PD. Positivity of iron studies in pruritus of unknown origin. J Eur Acad Dermatol Venereol 2008; 22: 617–8PubMedCrossRefGoogle Scholar
  65. 65.
    Ganesh A, Maxwell LG. Pathophysiology and management of opioid-induced pruritus. Drugs 2007; 67: 2323–33PubMedCrossRefGoogle Scholar
  66. 66.
    Kjellberg F, Trame`r MR. Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. Eur J Anaesthesiol 2001; 18: 346–57PubMedGoogle Scholar
  67. 67.
    Charuluxananan S, Kyokong O, Somboonviboon W, et al. Nalbuphine versus propofol for treatment of intrathecal morphine-induced pruritus after cesarean delivery. Anesth Analg 2001; 93: 162–5PubMedCrossRefGoogle Scholar
  68. 68.
    Bonnet MP, Marret E, Josserand J, et al. Effect of prophylactic 5-HT3 receptor antagonists on pruritus induced by neuraxial opioids: a quantitative systematic review. Br J Anaesth 2008; 101: 311–9PubMedCrossRefGoogle Scholar
  69. 69.
    Wang JJ, Ho ST, Tzeng JI. Comparison of intravenous nalbuphine infusion versus naloxone in the prevention of epidural morphine-related side effects. Reg Anesth Pain Med 1998; 23: 479–84PubMedGoogle Scholar
  70. 70.
    Cepeda MS, Africano JM, Manrique AM, et al. The combination of low dose of naloxone and morphine in PCA does not decrease opioid requirements in the postoperative period. Pain 2002; 96: 73–9PubMedCrossRefGoogle Scholar
  71. 71.
    Yeh YC, Lin TF, Lin FS, et al. Combination of opioid agonist and agonistantagonist: patient-controlled analgesia requirement and adverse events among different-ratio morphine and nalbuphine admixtures for postoperative pain. Br J Anaesth 2008; 101: 542–8PubMedCrossRefGoogle Scholar
  72. 72.
    Sheen MJ, Ho ST, Lee CH, et al. Prophylactic mirtazapine reduces intrathecal morphine-induced pruritus. Br J Anaesth 2008; 101: 711–5PubMedCrossRefGoogle Scholar
  73. 73.
    Sheen MJ, Ho ST, Lee CH, et al. Preoperative gabapentin prevents intrathecal morphine-induced pruritus after orthopedic surgery. Anesth Analg 2008; 106: 1868–72PubMedCrossRefGoogle Scholar
  74. 74.
    Litt JZ. Litt’s drug eruption reference manual. 13th ed. London: Taylor & Francis, 2006: 1–800Google Scholar
  75. 75.
    Reich A, Stönder S, Szepietowski JC. Drug-induced pruritus: a review. Acta Derm Venereol 2009; 89: 236–44PubMedCrossRefGoogle Scholar
  76. 76.
    Agbabiaka TB, Savović J, Ernst E.Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf 2008; 31: 21–37PubMedCrossRefGoogle Scholar
  77. 77.
    Streckelings UM, Artuc M, Wollschager T, et al. Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions. Acta Derm Venereol 2001; 81: 321–5CrossRefGoogle Scholar
  78. 78.
    Bingham LG, Noble JW, Davis MD. Wet dressings used with topical corticosteroids for pruritic dermatoses: a retrospective study. J Am Acad Dermatol 2009; 60: 792–800PubMedCrossRefGoogle Scholar
  79. 79.
    O’Donoghue M, Tharp MD. Antihistamines and their role as antipruritics. Dermatol Ther 2005; 18: 333–40PubMedCrossRefGoogle Scholar
  80. 80.
    Huang JF, Thurmond RL. The new biology of histamine receptors. Curr Allergy Asthma Rep 2008; 8: 21–7PubMedCrossRefGoogle Scholar
  81. 81.
    Schulz S, Metz M, Siepmann D, et al. Antipruritische Wirksamkeit einer hoch dosierten Antihistaminikatherapie: Ergebnisse einer retrospektiv analysierten Fallserie. Hautarzt 2009; 60: 564–8PubMedCrossRefGoogle Scholar
  82. 82.
    Rombold S, Lobisch K, Katzer K, et al. Efficacy of UVA1 phototherapy in 230 patients with various skin diseases. Photodermatol Photoimmunol Photomed 2008; 24: 19–23PubMedCrossRefGoogle Scholar
  83. 83.
    Gambichler T, Hyun J, Sommer A, et al. A randomised controlled trial on photo(chemo)therapy of subacute prurigo. Clin Exp Dermatol 2006; 31: 348–53PubMedCrossRefGoogle Scholar
  84. 84.
    Stander S, Weisshaar E, Luger TA. Neurophysiological and neurochemical basis of modern pruritus treatment. Exp Dermatol 2008; 17: 161–9PubMedCrossRefGoogle Scholar
  85. 85.
    Bigliardi PL, Stammer H, Jost G, et al. Treatment of pruritus with topically applied opiate receptor antagonist. J Am Acad Dermatol 2007; 56: 979–88PubMedCrossRefGoogle Scholar
  86. 86.
    Eberlein B, Eicke C, Reinhardt HW, et al. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol 2008; 22: 73–82PubMedGoogle Scholar
  87. 87.
    Yesudian PD, Wilson NJ. Efficacy of gabapentin in the management of pruritus of unknown origin. Arch Dermatol 2005; 141: 1507–9PubMedCrossRefGoogle Scholar
  88. 88.
    Shneker BF, McAuely JW. Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacoter 2005; 39: 2029–37CrossRefGoogle Scholar
  89. 89.
    Brune A, Metze D, Luger TA, et al. Antipruritische Therapie mit dem oralen Opiatrezeptorantagonisten Naltrexon: Offene, nicht placebokontrollierte Anwendung bei 133 Patienten. Hautarzt 2004; 55: 1130–6PubMedCrossRefGoogle Scholar
  90. 90.
    Ajayi AA, Kolawole BA, Udoh SJ. Endogenous opioids, mu-opiate receptors and chloroquine-induced pruritus: a double-blind comparison of naltrexone and promethazine in patients with malaria fever who have an established history of generalized chloroquine-induced itching. Int J Dermatol 2004; 43: 972–7PubMedCrossRefGoogle Scholar
  91. 91.
    Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol 2006; 54: 527–31PubMedCrossRefGoogle Scholar
  92. 92.
    Greaves MW. Itch in systemic disease: therapeutic options.Dermatol Ther 2005; 18: 323–7PubMedCrossRefGoogle Scholar
  93. 93.
    Hundley JL, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol 2004; 50: 889–91PubMedCrossRefGoogle Scholar
  94. 94.
    Zylicz Z, Krajnik M, Sorge AA, et al. Paroxetine in the treatment of severe nondermatological pruritus: a randomized, controlled trial. J Pain Symptom Manage 2003; 26: 1105–12PubMedCrossRefGoogle Scholar
  95. 95.
    Ständer S, Böckenholt B, Schürmeyer-Horst F, et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol 2009; 89: 45–51PubMedGoogle Scholar
  96. 96.
    Krasowska D, Szymanek M, Schwartz RA, et al. Cutaneous effects of the most commonly used antidepressant medication, the selective serotonin reuptake inhibitors. J Am Acad Dermatol 2007; 56: 848–53PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Nicoletta Cassano
    • 1
  • Gianpaolo Tessari
    • 2
    Email author
  • Gino A. Vena
    • 1
  • Giampiero Girolomoni
    • 2
  1. 1.Second Dermatology Clinic MIDIM DepartmentUniversity of BariBariItaly
  2. 2.Section of Dermatology and Venereology, Department of Biomedical and Surgical SciencesUniversity of VeronaVeronaItaly

Personalised recommendations